This inventor holds 1 USPTO granted patent and 2 published patent applications and 3 EPO patents. Top assignee: Richter Gedeon Nyrt.. Active years: 2012.
Company Filing History:
Years Active: 2012
Title: The Innovative Contributions of Tamás Gáti
Introduction
Tamás Gáti is a notable inventor based in Budapest, Hungary. He has made significant contributions to the field of pharmaceuticals, particularly in the production of ezetimibe, a medication used to lower cholesterol levels. His work exemplifies the intersection of chemistry and medicine, showcasing the importance of innovation in healthcare.
Latest Patents
Tamás Gáti holds a patent for a process for the production of ezetimibe and intermediates used in this process. The patent details a method for producing 1-(4-3(R)-[3(S)-(4-fluorophenyl)-3-hydroxypropyl]-4(S)-(4-hydroxyphenyl)-2-azetidinone (ezetimibe) through a series of reaction schemes. The substances involved in this process are represented by various general formulas, with some being new compounds. This innovative approach highlights Gáti's expertise in synthetic chemistry.
Career Highlights
Tamás Gáti is associated with Richter Gedeon Nyrt., a prominent pharmaceutical company in Hungary. His role at the company has allowed him to contribute to important advancements in drug development. Gáti's work is characterized by a commitment to improving health outcomes through innovative pharmaceutical solutions.
Collaborations
Throughout his career, Tamás Gáti has collaborated with esteemed colleagues such as János Éles and József Bódi. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and expertise, further enhancing the quality of their research and development efforts.
Conclusion
Tamás Gáti's contributions to the field of pharmaceuticals, particularly through his patent on ezetimibe production, underscore the vital role of inventors in advancing healthcare. His work not only reflects his personal dedication to innovation but also the collaborative spirit of the scientific community.
